Lasix (Furosemide Sodium)

Furosemide blocks the Na⁺/K⁺/2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. This inhibition stops the reabsorption of sodium, chloride, and water, leading to a marked increase in urinary excretion of these substances and a consequent reduction in extracellular fluid volume.

The appropriate dose of Lasix is determined by the prescribing clinician based on the patient’s condition, severity of edema, renal function, and response to therapy. Dosage may be adjusted during treatment, and the exact regimen should always follow the healthcare professional’s orders.

Lasix is classified as Pregnancy Category B, indicating that animal studies have not shown risk, but there are no well‑controlled studies in pregnant women. It should be used only if the potential benefit justifies any possible risk to the fetus. Limited data are available for breastfeeding, so a doctor’s advice is essential.

To order Lasix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lasix belongs to the loop diuretic class, which is more potent than thiazide diuretics and works earlier in the nephron. It is preferred for rapid and substantial fluid removal in severe edema, whereas thiazides are often used for mild hypertension. Loop diuretics also have a higher risk of electrolyte disturbances.

Lasix injectable solution should be stored at 2‑8 °C, kept refrigerated, protected from light, and never frozen or shaken. Maintain the original packaging to preserve sterility, and discard any solution that appears discolored or contains particles.

Lasix is given by intramuscular or intravenous injection. For IV use, it is often diluted in compatible fluids and administered slowly to reduce the risk of ototoxicity. The exact route, concentration, and infusion rate are determined by the prescribing clinician based on the clinical situation.

Serious risks include severe electrolyte imbalances (especially low potassium or sodium), acute kidney injury, ototoxicity leading to permanent hearing loss, and profound hypotension that can cause shock. Patients should be monitored closely for these complications, particularly during high‑dose or rapid IV administration.

Lasix is contraindicated in patients with anuria (no urine output), known hypersensitivity to furosemide or sulfonamides, severe electrolyte depletion, and in those with significant hearing impairment when high doses are required. Caution is also advised for patients with severe liver disease, uncontrolled diabetes, or those taking interacting medications.